Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

Phase 4

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2005-11-11

Last Posted Date: 2011-05-18

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 300

Registration Number: NCT00252668

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: sulphasalazine (SSZ)
Drug: etanercept

First Posted Date: 2005-11-02

Last Posted Date: 2012-11-08

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 566

Registration Number: NCT00247962

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: etanercept
Drug: Placebo

First Posted Date: 2005-10-28

Last Posted Date: 2022-01-31

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 752

Registration Number: NCT00245960

Locations: 🇩🇪
SCIderm GmbH Hamburg, Hamburg, Germany
🇩🇪
Klinikum Innenstadt der Universitaet Muenchen, Muenchen, Germany
🇭🇺
Medical University of Szeged, Szeged, Hungary

and more 109 locations

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Phase 2

Completed

Conditions: Graft vs Host Disease
Immune System Disorders

Interventions: Drug: Pentostatin
Drug: Mycophenolate Mofetil
Drug: Etanercept
Drug: Denileukin Diftitox

First Posted Date: 2005-09-23

Last Posted Date: 2021-11-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 180

Registration Number: NCT00224874

Locations: 🇺🇸
DFCI/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States

and more 16 locations